AS03 adjuvant

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority

Conditions

InfluenzaInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 Subtype

Phase 1

H5N1 Mix and Match With AS03

CompletedNCT01317758

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2011-05-31End: 2012-09-30Updated: 2013-01-18

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

CompletedNCT02957656

National Institute of Allergy and Infectious Diseases (NIAID)Influenza A Virus, H7N9 Subtype

Start: 2016-12-31Updated: 2018-10-02

Phase 2

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

CompletedNCT03497845

Biomedical Advanced Research and Development AuthorityInfluenza A Virus, H5N1 Subtype

Start: 2018-03-15End: 2019-11-19Updated: 2020-07-14

Related Papers

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

npj Vaccines2022-08-3020 citations

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant

Open Forum Infectious Diseases2014-01-0131 citations